The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer
Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label study done in 3 hospitals in China. Patients with stage IIIB
and IIIC gastric cancer who undergo curative D2 gastrostomy will be randomly assigned after
surgery to receive adjuvant chemotherapy with oxaliplatin and capecitabine, or adjuvant
chemotherapy combined Traditional Chinese treatment. The primary outcome was disease-free
survival and 3-year disease-free survival rate in the intention-to-treat population.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Shanghai University of Traditional Chinese Medicine
Collaborators:
Jiangsu Province Hospital of Traditional Chinese Medicine RenJi Hospital